Market Research Logo

Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry

Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry

Summary

Rheumatic disorders are a wide range of conditions which are characterized by chronic pain, with some of the most common conditions being osteoarthritis (OA) and rheumatoid arthritis (RA), and it is estimated that about one in four adults in America are diagnosed with a rheumatic disorder. The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.

The rheumatic disorders market is expected to see good growth over the forecast period, increasing from $58.97 billion in 2017 at a compound annual growth rate (CAGR) of 4.46%. The US market accounted for approximately 43% of the global market in the baseline year 2017, and this is projected to remain stable over the forecast period.

The incidence of many indications within the rheumatic disorders therapy area continues to rise and as the global population ages prevalence will increase which is a key driver of market growth. By way of example, the total population living with OA across the seven major markets is expected to increase from 125.76 million in 2017 to 138.44 million in 2024. Market growth will also be driven by the entry of new products to the market, with two drug classes in particular driving strong market growth.

The rheumatic disorders market is dominated by a number of blockbuster drugs, which target tumor necrosis alpha (TNF-α), a key pro-inflammatory cytokine. However, due to several recent and upcoming patent expiries, this drug class will suffer from biosimilar erosion over the forecast period, resulting in revenue decline and reduced market dominance.

The therapy market is dominated by top pharmaceutical companies with 18 of the top 20 pharma companies having at least one marketed or pipeline rheumatic disorders product. By 2024, the 10 companies generating the most revenue in the rheumatic disorders therapy area are all top 20 pharmaceutical companies.

The report Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.

Forecast projections to 2024 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major drug classes are provided within the report.

Scope

  • How is the rheumatic disorders landscape expected to change?
  • Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?
  • Overall, there are 1,069 products in the rheumatic disorder pipeline, how does the composition of the pipeline compare with that of the existing market?
  • Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?
  • The market size for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in 2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will contribute to market growth most, and which will achieve blockbuster status?
  • What types of companies are involved in the rheumatic disorder therapy area?
  • Will the current market leaders retain their dominance over the forecast period?
  • How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?
Reasons to buy

This report will allow you to -
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the five key indications
  • Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the rheumatic disorder drug market
  • Identify trends and developments in the rheumatic disorder pipeline and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates
  • Identify which two drug classes will see particularly strong market growth over the forecast period
  • See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion
  • Identify commercial opportunities in the rheumatic disorder deal landscape by analyzing trends in licensing and co-development deals


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Therapy Area Overview
      • Rheumatoid Arthritis
      • Osteoarthritis
      • Osteoporosis
      • Systemic Lupus Erythematosus
      • Psoriatic Arthritis
    • Etiology
      • Table Rheumatic Disorders Drugs Market, Global, Etiology of RA, OA, Osteoporosis, SLE and PsA, 2018
    • Pathophysiology
      • Rheumatoid Arthritis
      • Osteoarthritis
      • Osteoporosis
      • Systemic Lupus Erythematosus
      • Psoriatic Arthritis
    • Epidemiology Patterns and Forecasts – Prevalence and Patient Segmentation
      • Table Rheumatic Disorders Drugs Market, 7MM, Epidemiology of Key Rheumatic Disorders Indications, 2018
      • Rheumatoid Arthritis
        • Table Figure 1: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Rheumatoid Arthritis, 2017–2024
      • Osteoarthritis
        • Table Figure 2: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Osteoarthritis, 2017–2024
      • Osteoporosis
        • Table Figure 3: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Osteoporosis, 2017–2024
      • Systemic Lupus Erythematosus
        • Table Figure 4: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Systemic Lupus Erythematosus, 2017–2024
      • Psoriatic arthritis
        • Table Figure 5: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Psoriatic Arthritis, 2017–2024
    • Treatment
      • Rheumatoid Arthritis
        • Table Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within RA, 2018
        • Table Rheumatic Disorders Drugs Market, Global, Off-label Treatments for RA, 2018
      • Osteoarthritis
        • Table Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within OA, 2018
        • Table Rheumatic Disorders Drugs Market, Global, Off-label Treatments for OA, 2018
      • Osteoporosis
        • Table Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within Osteoporosis, 2018
        • Table Rheumatic Disorders Drugs Market, Global, Off-label Treatments for Osteoporosis, 2018
      • Systemic Lupus Erythematosus
        • Table Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within SLE, 2018
        • Table Rheumatic Disorders Drugs Market, Global, Off-label Treatments for SLE, 2018
      • Psoriatic Arthritis
        • Table Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within PsA, 2018
        • Table Rheumatic Disorders Drugs Market, Global, Off-label Treatments for PsA, 2018
  • Key Marketed Products
    • Overview
      • Table Rheumatic Disorders Drugs Market, Global, Key Marketed Products Overview, 2018
    • Humira (adalimumab) –AbbVie
      • Table Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Humira, 2018
      • Table Figure 6: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Humira ($bn), 2006–2024
    • Enbrel (etanercept) –Amgen
      • Table Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Enbrel, 2018
      • Table Figure 7: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006–2024
    • Simponi (golimumab) –Johnson & Johnson
      • Table Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Simponi, 2018
      • Table Figure 8: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Simponi ($bn), 2010–2024
    • Remicade (infliximab) –Johnson & Johnson
      • Table Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Remicade, 2018
      • Table Figure 9: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006–2024
    • Rituxan (rituximab) –Roche
      • Table Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Rituxan, 2018
      • Table Figure 10: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006–2024
    • Stelara (ustekinumab) –Johnson & Johnson
      • Table Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Stelara, 2018
      • Table Figure 11: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Stelara ($bn), 2010–2024
    • Cosentyx (secukinumab) –Novartis
      • Table Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Cosentyx, 2018
      • Table Figure 12: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015–2024
    • Prolia (denosumab) –Amgen
      • Table Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Prolia, 2018
      • Table Figure 13: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Prolia ($bn), 2010–2024
    • Orencia (abatacept) –Bristol-Myers Squibb
      • Table Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Orencia, 2018
      • Table Figure 14: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Orencia ($bn), 2014–2023
    • Actemra (tocilizumab) –Roche
      • Table Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Actemra, 2018
      • Table Figure 15: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Actemra ($bn), 2016–2024
    • Benlysta (belimumab) –GlaxoSmithKline
      • Table Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Benlysta, 2018
      • Table Figure 16: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Benlysta ($m), 2011–2024
    • Forteo (teriparatide) –Eli Lilly
      • Table Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Forteo, 2018
      • Table Figure 17: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Forteo ($bn), 2006–2024
  • Pipeline Landscape Assessment
    • Overview
      • Table Figure 18: Rheumatic Disorders Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
    • Pipeline Development Landscape
      • Table Figure 19: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Pipeline by Stage of Development, Molecule Type and Program Type, 2018
      • Table Figure 20: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Stage of Development, 2018
    • Molecule Types in the Pipeline
      • Table Figure 21: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Molecule Type, 2018
    • Molecular Targets in the Pipeline
      • Table Figure 22: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Pipeline by Molecular Target, 2018
      • Table Figure 23: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Molecular Target, 2018
    • Clinical Trials Landscape
      • Clinical Trial Failure Rates
        • Table Figure 24: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Attrition Rate by Stage of Development (%), 2006–2018
        • Table Figure 25: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006–2018
        • Table Figure 26: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006–2018
        • Table Figure 27: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target and Stage of Development (%), 2006–2018
      • Clinical Trial Duration
        • Table Figure 28: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2018
        • Table Figure 29: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006–2018
        • Table Figure 30: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006–2018
        • Table Figure 31: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006–2018
      • Clinical Trial Size
        • Table Figure 32: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2018
        • Table Figure 33: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006–2018
        • Table Figure 34: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006–2018
        • Table Figure 35: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (participants), 2006–2018
      • Cumulative Clinical Program Size
        • Table Figure 36: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2018
        • Table Figure 37: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006–2018
        • Table Figure 38: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006–2018
        • Table Figure 39: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Molecular Target and Stage of Development (participants), 2006–2018
    • Assessment of Key Pipeline Products
      • Upadacitinib tartrate – AbbVie
        • Table Figure 40: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Upadacitinib tartrate ($bn), 2019–2024
      • Filgotinib – Gilead Sciences
        • Table Figure 41: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Filgotinib ($bn), 2019–2024
      • Lenabasum – Corbus Pharmaceuticals
        • Table Figure 42: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Lenabasum ($bn), 2021–2024
      • Evenity (romosozumab) –Amgen / UCB / Astellas
        • Table Figure 43: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Evenity (romosozumab) ($m), 2019–2024
      • Avacopan – ChemoCentryx
        • Table Figure 44: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Avacopan ($m), 2021–2024
      • Pegadricase – Selecta Biosciences
        • Table Figure 45: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Pegadricase ($m), 2020–2024
      • Anifrolumab – AstraZeneca
        • Table Figure 46: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Anifrolumab ($m), 2019–2024
  • Multi-scenario Market Forecast to 2024
    • Overall Market Size
      • Table Figure 47: Rheumatic Disorders Drugs Market, Global, Market Size ($bn), 2017–2024
      • Table Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017–2024
    • Generic Penetration
      • Table Figure 48: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017–2024
      • Table Rheumatic Disorders Drugs Market, Global, Use of Generics Across Key Indications, 2018
    • Revenue Forecast by Molecular Target
      • Products Acting on Tumor Necrosis Factor-Alpha
        • Table Figure 49: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on TNF- ($bn), 2017–2024
      • Products Acting on Interleukins and Interleukin Receptors
        • Table Figure 50: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Interleukins and Interleukin Receptors ($bn), 2017–2024
      • Products Acting on Protein Kinases
        • Table Figure 51: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Protein Kinases ($bn), 2017–2024
      • Products Acting on Cell Surface Antigens
        • Table Figure 52: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Targeting Cell Surface Antigens ($bn), 2017–2024
      • Products Acting on Hormones and Hormone Receptors
        • Table Figure 53: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Hormones and Hormone Receptors ($bn), 2017–2024
  • Company Analysis and Positioning
    • Table Figure 54: Rheumatic Disorders Drugs Market, Global, Company Analysis Matrix, 2017–2024
    • Table Figure 55: Rheumatic Disorders Drugs Market, Global, Cluster by Growth and Market Share, 2017–2024
    • Revenue and Market Share Analysis by Company
      • Table Rheumatic Disorders Drugs Market, Global, Forecast Revenue by Company (%), 2017–2024
      • Table Figure 56: Rheumatic Disorders Drugs Market, Global, Forecast Market Share by Company (%), 2017–2024
      • Table Figure 57: Rheumatic Disorders Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017–2024
      • Table Figure 58: Rheumatic Disorders Market, Global, Revenues by Route of Acquisition, 2017–2024
      • AbbVie
        • Table Figure 59: Rheumatic Disorders Drugs Market, Global, AbbVie Annual Revenue Forecast ($bn), 2017–2024
      • Amgen
        • Table Figure 60: Rheumatic Disorders Drugs Market, Global, Amgen Annual Revenue Forecast ($bn), 2017–2024
      • Johnson & Johnson
        • Table Figure 61: Rheumatic Disorders Drugs Market, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2017–2024
      • Novartis
        • Table Figure 62: Rheumatic Disorders Drugs Market, Global, Novartis Annual Revenue Forecast ($bn), 2017–2024
      • Pfizer
        • Table Figure 63: Rheumatic Disorders Drugs Market, Global, Pfizer Annual Revenue Forecast ($bn), 2017–2024
      • Roche
        • Table Figure 64: Rheumatic Disorders Drugs Market, Global, Roche Annual Revenue Forecast ($bn), 2017–2024
      • Eli Lilly
        • Table Figure 65: Rheumatic Disorders Drugs Market, Global, Eli Lilly Annual Revenue Forecast ($bn), 2017–2024
      • Bristol-Myers Squibb
        • Table Figure 66: Rheumatic Disorders Drugs Market, Global, Bristol-Myers Squibb Annual Revenue Forecast ($bn), 2017–2024
    • Company Landscape
      • Table Figure 67: Rheumatic Disorders Drugs Market, Global, Companies by Type, 2018
    • Marketed and Pipeline Portfolio Analysis
      • Table Figure 68: Rheumatic Disorders Drugs Market, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Rheumatic Disorders Specialization, 2018
      • Table Figure 69: Rheumatic Disorders Drugs Market, Global, Proportion of Total Company Revenue Attributed to Rheumatic Disorders, 2017–2024
  • Strategic Consolidations
    • Licensing Deals
      • Deals by Region, Year and Value
        • Table Figure 70: Rheumatic Disorders Drugs Market, Global, Licensing Deals by Region, Year and Value, 2006–2018
      • Deals by Indication and Value
        • Table Figure 71: Rheumatic Disorders Drugs Market, Global, Licensing Deals by Indication, 2006–2018
      • Deals by Stage of Development and Value
        • Table Figure 72: Rheumatic Disorders Drugs Market, Global, Licensing Deals by Stage of Development and Value, 2006–2018
      • Deals by Molecule Type, Molecular Target and Value
        • Table Figure 73: Rheumatic Disorders Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2018
      • Licensing Deals with Disclosed Values
        • Table Figure 74: Rheumatic Disorders Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018
    • Co-development Deals
      • Deals by Region, Year and Value
        • Table Figure 80: Rheumatic Disorders Drugs Market, Global, Co-development Deals by Region, Year and Value, 2006–2018
      • Deals by Indication and Value
        • Table Figure 81: Rheumatic Disorders Drugs Market, Global, Co-development Deals by Indication, 2006–2018
      • Deals by Stage of Development and Value
        • Table Figure 82: Rheumatic Disorders Drugs Market, Global, Co-development Deals by Stage of Development and Value, 2006–2018
      • Deals by Molecule Type, Molecular Target and Value
        • Table Figure 83: Rheumatic Disorders Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2018
      • Co-development Deals with Disclosed Values
        • Table Figure 84: Rheumatic Disorders Drugs Market, Global, Co-development Deals with Disclosed Values, 2006–2018
  • Appendix
    • References
    • Figures of All Clinical Stage Pipeline Products
      • Table Figure 87: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017
    • Abbreviations
    • Disease List
    • Methodology
      • Coverage
      • Secondary Research
      • Market Size and Revenue Forecasts
      • Pipeline Analysis
      • Competitive Landscape
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report